Care choices

What can a care visit help you compare?

Bring the goal you want help with. Leave room for the answer to be broader than a drug name.

Semaglutide has approved products

Semaglutide (Wegovy, Ozempic) is a different ingredient from cagrilintide.

Wegovy had Food and Drug Administration (FDA) approval for adult weight care as of September 26, 2026.Read the Wegovy product information

The product label is the official information about use and warnings. Wegovy's label pairs the medicine with changes in eating and activity.

Its adult use covers two groups: people with obesity, or people with overweight and a weight-related health problem. High blood pressure is one example of such a problem. These weight groups are based on BMI, a number calculated from weight and height. In the trials behind this use, obesity meant a BMI of 30 or above. Overweight meant a BMI from 27 to below 30, with a weight-related health problem.

Ask the person treating you to explain which group applies to you.

Ozempic's approved uses are for adults with type 2 diabetes, a form of diabetes involving high blood sugar. As of September 26, 2026, its label did not approve use for weight loss.Read the Ozempic product label

Ask which exact product is being discussed and what health goal the visit is addressing.

An approved medicine still has things to weigh

Semaglutide labels carry a boxed warning, FDA's strongest warning format. It concerns tumors, or abnormal growths, in the thyroid, a small body part in the neck. Those tumors were found in studies of rats and mice.

The labels say it is not known whether semaglutide causes those tumors in people.

The Wegovy label also warns about severe stomach trouble. Fluid loss from bad vomiting or diarrhea, meaning loose stools, can harm the kidneys.

Ask for the possible benefit, the possible problems, and the follow-up plan in words you understand. A larger weight-loss number is only part of that conversation.

Ask how the whole plan would work

What would we track besides weight? How would we decide whether the plan is helping? What would happen if the medicine did not suit me?

Ask about the cost of ongoing visits and what support comes with the plan. Take time to get clear answers before making a choice.